NCT04196530: BDB001-102 Open Label Dose Escalation Combination w Atezolizumab

NCT04196530
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active untreated unstable CNS metastases and/or carcinomatous meningitis – see trial for details; Patients with prior exposure to TLR7 agonists (e.g. GS-9620, imiquimod, TMX 101, resiquimod, MEDI9197, 825A) or TLR9 agonists (e.g. SD-101, tilsotolimod (IMO-2125), MGN1703, GNKG168, DUK-CPG-001, CMP-001)
https://ClinicalTrials.gov/show/NCT04196530

Comments are closed.

Up ↑